Sells prescription medicines to pharmacies, distributors and wholesalers for blood cancers, other cancers, and inflammatory and autoimmune diseases.
10-K for FY2025, filed Feb 10, 2026We are focused in three therapeutic areas that are defined by the indications of our approved medicines and the diseases for which our…View ↗
Our hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI…View ↗
Our oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical…View ↗
Product revenues are recognized at a point in time once we satisfy the performance obligation and control is transferred under the revenue…View ↗
Most revenue comes from selling medicines to pharmacies, distributors and wholesalers; sales count when customers receive the products. Incyte also earns royalties on partners’ sales and license or milestone payments through collaborations, with milestone revenue counted when the milestone is achieved.
10-K for FY2025, filed Feb 10, 2026Product revenues are recognized at a point in time once we satisfy the performance obligation and control is transferred under the revenue…View ↗
Product revenues are recognized once we satisfy the performance obligation at a point in time under the revenue recognition criteria as…View ↗
Royalty revenues on commercial sales for ruxolitinib (marketed as JAKAVI® outside the United States) by Novartis Pharmaceutical…View ↗
Out-licensing arrangements contain the right to use functional intellectual property, which is the underlying performance obligation of…View ↗
Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to…View ↗
10-K for FY2025, filed Feb 10, 2026
FY2025 revenue by product or service ↗$5.2B
10-K for FY2025, filed Feb 10, 2026
$5.2B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenues, net
Sold outright
10-K for FY2025, filed Feb 10, 2026 |
85%
FY2022: 81%
|
Product revenues, net, FY2025
$4.4B Sources
|
Sold outright |
|
Product royalty revenues
Licensed
10-K for FY2025, filed Feb 10, 2026 |
12%
FY2022: 14%
|
Product royalty revenues, FY2025
$636.9M Sources
|
Licensed |
|
Milestone and contract revenues
|
2.9%
FY2022: 4.9%
|
Milestone and contract revenues, FY2025
$150M Sources
|
In the United States, Incyte sells to specialty and retail pharmacies, specialty distributors and wholesalers; in Europe and some other markets, it sells to retail and hospital pharmacies and distributors. PEMAZYRE sales in Japan go to an exclusive wholesaler.
10-K for FY2025, filed Feb 10, 2026Product revenues are recognized at a point in time once we satisfy the performance obligation and control is transferred under the revenue…View ↗
Yes. It kept 25 cents of every revenue dollar as net income in FY2025 and turned 26 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
−$784.8MView ↗
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Jul 6, 2026
WILMINGTON, Del. – July 6, 2026 – Incyte (Nasdaq:INCY) announced today it has completed its acquisition of Vega Therapeutics, Inc., a…View ↗
Growing. Revenue grew 73% in 4 years, from $3B in FY2021 to $5.2B in FY2025, about 15% a year.
Tafasitamab rights
In the older report, Incyte co-commercialized tafasitamab in the United States with MorphoSys and held exclusive rights outside the United States; the latest report says it holds exclusive global rights after buying the rights from MorphoSys.
10-K for FY2022, filed Feb 7, 2023 10-K for FY2025, filed Feb 10, 2026In January 2020, we and MorphoSys AG entered into a collaboration and license agreement to further develop and commercialize MorphoSys’…View ↗
In January 2020, we and MorphoSys AG (“MorphoSys”) entered into a collaboration and license agreement to further develop and commercialize…View ↗
Loading...